Obesity is distinguished by a body mass index (BMI) greater than 30. Tremmel et al. (2017) reports obese individuals are at a greater risk for developing cardiovascular disease, diabetes, and cancer. In 2014, approximately 641 million adults were classified as obese (Zhang et al., 2018). This epidemic has drastically worsened over the last two decades resulting in obesity ranking as the fifth most common cause of death globally (Safaei et al., 2021). Okunogbe et al. (2021) states, slowing the incidence rate of obesity by 5% will save approximately $3.3 billion annually between 2020-2060. The pathophysiology and cause of obesity is multifactorial, therefore, interventions to decrease weight and associated comorbid risk factors and diseases must also be complex.

The purpose of this Benchmark project is to implement an evidence-based multifaceted approach to reduce the incidence of obesity and related comorbidities of patients in an outpatient clinic setting. Literature reveals that a combination of interventions, such as semaglutide injections used as an adjunct to lifestyle changes (diet and exercise), provides superior results in weight loss and reduced comorbid risk factors compared to lifestyle adjustments alone. Noteworthy results for a combination intervention approach compared to a singular intervention include improved weight, waist circumference, lipid panels, blood pressure, glucose and insulin levels, and glycated hemoglobin (HbA1c). The most commonly reported adverse effects of GLP-1 receptor antagonists such as liraglutide or semaglutide include gastrointestinal consequences (Garvey et al., 2020 & Kelly et al., 2020).

Date of publication

Fall 11-5-2023

Document Type

MSN Capstone Project



Persistent identifier



Masters of Science in Nursing, Family Nurse Practitioner